JP2004501650A - 複製欠損アデノウイルスｔｎｆベクター - Google Patents
複製欠損アデノウイルスｔｎｆベクター Download PDFInfo
- Publication number
- JP2004501650A JP2004501650A JP2002506221A JP2002506221A JP2004501650A JP 2004501650 A JP2004501650 A JP 2004501650A JP 2002506221 A JP2002506221 A JP 2002506221A JP 2002506221 A JP2002506221 A JP 2002506221A JP 2004501650 A JP2004501650 A JP 2004501650A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- region
- genome
- adenovirus vector
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 245
- 239000013598 vector Substances 0.000 title claims abstract description 214
- 230000002950 deficient Effects 0.000 title claims abstract description 41
- 230000010076 replication Effects 0.000 title claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 70
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 58
- 125000006850 spacer group Chemical group 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 34
- 201000011510 cancer Diseases 0.000 claims abstract description 6
- 230000001093 anti-cancer Effects 0.000 claims abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 66
- 230000014509 gene expression Effects 0.000 claims description 37
- 230000005855 radiation Effects 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 27
- 230000008488 polyadenylation Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 14
- 108091026890 Coding region Proteins 0.000 claims description 11
- 101710145505 Fiber protein Proteins 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 230000005030 transcription termination Effects 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 15
- 239000004475 Arginine Substances 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 238000010586 diagram Methods 0.000 abstract description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 62
- 108090000623 proteins and genes Proteins 0.000 description 40
- 239000000047 product Substances 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 20
- 101710132601 Capsid protein Proteins 0.000 description 18
- 101710094648 Coat protein Proteins 0.000 description 18
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 18
- 101710125418 Major capsid protein Proteins 0.000 description 18
- 101710141454 Nucleoprotein Proteins 0.000 description 18
- 101710083689 Probable capsid protein Proteins 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 15
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 239000000835 fiber Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 9
- 101710096438 DNA-binding protein Proteins 0.000 description 9
- 241001135569 Human adenovirus 5 Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241000700584 Simplexvirus Species 0.000 description 5
- 102000006601 Thymidine Kinase Human genes 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 108010006025 bovine growth hormone Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 3
- 241000701822 Bovine papillomavirus Species 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 238000001823 molecular biology technique Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101900067218 Human cytomegalovirus Viral transcription factor IE2 Proteins 0.000 description 2
- 101150090364 ICP0 gene Proteins 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical group CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 108700025771 adenovirus penton Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000015936 AP-1 transcription factor Human genes 0.000 description 1
- 108050004195 AP-1 transcription factor Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- -1 Apo2L Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100026549 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 101150091887 Ctla4 gene Proteins 0.000 description 1
- 102100037912 Cyclin-dependent kinase 11A Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
- 101710091772 Death domain-associated protein 6 Proteins 0.000 description 1
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101100321993 Drosophila melanogaster pix gene Proteins 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000738403 Homo sapiens Cyclin-dependent kinase 11A Proteins 0.000 description 1
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 101900065606 Human cytomegalovirus Immediate early protein IE1 Proteins 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 101710101995 Pre-hexon-linking protein IIIa Proteins 0.000 description 1
- 101710197985 Probable protein Rev Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000009040 Sp Transcription Factors Human genes 0.000 description 1
- 108010049181 Sp Transcription Factors Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 1
- 101710189834 Transcription factor AP-2-alpha Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 101150094182 UL84 gene Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical class 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/604,694 US6579522B1 (en) | 2000-06-27 | 2000-06-27 | Replication deficient adenoviral TNF vector |
| PCT/US2001/020536 WO2002000906A2 (en) | 2000-06-27 | 2001-06-27 | Replication deficient adenoviral tnf vector |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012022529A Division JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501650A true JP2004501650A (ja) | 2004-01-22 |
| JP2004501650A5 JP2004501650A5 (enExample) | 2008-07-31 |
Family
ID=24420637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002506221A Pending JP2004501650A (ja) | 2000-06-27 | 2001-06-27 | 複製欠損アデノウイルスｔｎｆベクター |
| JP2012022529A Pending JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012022529A Pending JP2012139220A (ja) | 2000-06-27 | 2012-02-03 | 複製欠損アデノウイルスｔｎｆベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6579522B1 (enExample) |
| EP (1) | EP1294918B1 (enExample) |
| JP (2) | JP2004501650A (enExample) |
| AT (1) | ATE306555T1 (enExample) |
| AU (2) | AU2001271549B2 (enExample) |
| CA (1) | CA2412637A1 (enExample) |
| DE (1) | DE60114006T2 (enExample) |
| WO (1) | WO2002000906A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009509544A (ja) * | 2005-10-01 | 2009-03-12 | チャールズ スタウト， | 調節可能な融合プロモーター |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1180159B1 (en) * | 1999-05-28 | 2008-09-03 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
| US6845929B2 (en) * | 2002-03-22 | 2005-01-25 | Ali Dolatabadi | High efficiency nozzle for thermal spray of high quality, low oxide content coatings |
| US20030223962A1 (en) * | 2002-06-03 | 2003-12-04 | Cornell Research Foundation, Inc. | Delivery of gene products to the lung parenchyma via gene transfer to the pleura |
| EP2168603A1 (en) | 2003-11-14 | 2010-03-31 | GenVec, Inc. | Therapeutic regimen for treating cancer |
| NZ546983A (en) * | 2003-11-24 | 2009-05-31 | Canji Inc | Reduction of dermal scarring |
| JP2008511336A (ja) * | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法 |
| WO2008112540A2 (en) * | 2007-03-09 | 2008-09-18 | Vectorlogics, Inc. | Cells for adenovirus vector and protein production |
| US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
| WO2011054811A1 (en) | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| US9458473B2 (en) | 2010-06-29 | 2016-10-04 | The Johns Hopkins University | Compositions and methods for retargeting virus constructs |
| KR101429696B1 (ko) * | 2012-11-21 | 2014-08-13 | 국립암센터 | 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2024233783A1 (en) | 2023-05-09 | 2024-11-14 | Cornell University | Expression cassette coding for vascular endothelial growth factor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11501219A (ja) * | 1995-11-28 | 1999-02-02 | ジェンベク、インコーポレイティッド | 細胞への遣伝子導入のためのベクターおよび方法 |
| JPH11502421A (ja) * | 1995-12-14 | 1999-03-02 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞株 |
| JPH11513390A (ja) * | 1995-10-06 | 1999-11-16 | アーチ デベロップメント コーポレイション | 細胞殺傷のウイルス増強のための方法および組成物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4879226A (en) | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| US5763209A (en) | 1988-09-26 | 1998-06-09 | Arch Development Corporation | Methods and materials relating to the functional domains of DNA binding proteins |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| JP3443119B2 (ja) * | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| CA2055168A1 (en) | 1990-11-21 | 1992-05-22 | Walter Fiers | Tnf-muteins |
| DK0563278T3 (da) | 1990-12-20 | 2000-08-21 | Dana Farber Cancer Inst Inc | Regulering af geneekspression med ioniserende stråling |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5968735A (en) | 1992-11-12 | 1999-10-19 | Max Delbruck-Centrum Fur Molekular Medizin Berlin | Vector for the expression of therapy-relevant genes |
| FR2709309B1 (fr) | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
| US5641755A (en) | 1994-02-04 | 1997-06-24 | Arch Development Corp. | Regulation of x-ray mediated gene expression |
| US5571797A (en) | 1994-05-11 | 1996-11-05 | Arch Development Corporation | Method of inducing gene expression by ionizing radiation |
| CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5962424A (en) | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
| WO1996027021A1 (en) | 1995-03-01 | 1996-09-06 | Cornell Research Foundation, Inc. | Interdependent adenoviral vectors and methods of using same |
| WO1996033746A1 (en) | 1995-04-28 | 1996-10-31 | Genetic Therapy, Inc. | Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines |
| US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| JP2002512501A (ja) | 1996-07-03 | 2002-04-23 | メリアル インコーポレイテッド | 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ） |
| CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| US5981275A (en) | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
| US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
| IL120979A0 (en) | 1997-06-02 | 1997-11-20 | Interpharm Lab Ltd | Glycosylated TNF |
| US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
| AU750803B2 (en) | 1997-10-29 | 2002-07-25 | University Of Pittsburgh | Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies |
| DE19747718A1 (de) | 1997-10-29 | 1999-05-06 | Baltzer Axel Wilhelm August Dr | Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie |
| AU1377299A (en) | 1997-11-03 | 1999-05-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona, The | Hyperthermic inducible expression vectors for gene therapy and methods of use thereof |
| WO1999046371A2 (en) | 1998-03-11 | 1999-09-16 | Board Of Regents, The University Of Texas System | Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| JP2002506651A (ja) | 1998-03-16 | 2002-03-05 | イントロジェン・セラピューティクス，インコーポレイテッド | 多重遺伝子ベクター |
| AU772963B2 (en) | 1998-04-24 | 2004-05-13 | Onyx Pharmaceuticals | Adenoviral vectors for treating disease |
| JP2002518341A (ja) | 1998-06-15 | 2002-06-25 | アーチ・デヴェロップメント・コーポレイション | 放射線療法と抗血管形成因子の組み合わせ |
| US6337338B1 (en) * | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
| US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
-
2000
- 2000-06-27 US US09/604,694 patent/US6579522B1/en not_active Expired - Fee Related
-
2001
- 2001-06-27 AU AU2001271549A patent/AU2001271549B2/en not_active Ceased
- 2001-06-27 AU AU7154901A patent/AU7154901A/xx active Pending
- 2001-06-27 DE DE60114006T patent/DE60114006T2/de not_active Expired - Lifetime
- 2001-06-27 CA CA002412637A patent/CA2412637A1/en not_active Abandoned
- 2001-06-27 JP JP2002506221A patent/JP2004501650A/ja active Pending
- 2001-06-27 EP EP01950575A patent/EP1294918B1/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/US2001/020536 patent/WO2002000906A2/en not_active Ceased
- 2001-06-27 AT AT01950575T patent/ATE306555T1/de not_active IP Right Cessation
-
2003
- 2003-04-25 US US10/424,638 patent/US20030175245A1/en not_active Abandoned
-
2012
- 2012-02-03 JP JP2012022529A patent/JP2012139220A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513390A (ja) * | 1995-10-06 | 1999-11-16 | アーチ デベロップメント コーポレイション | 細胞殺傷のウイルス増強のための方法および組成物 |
| JPH11501219A (ja) * | 1995-11-28 | 1999-02-02 | ジェンベク、インコーポレイティッド | 細胞への遣伝子導入のためのベクターおよび方法 |
| JPH11502421A (ja) * | 1995-12-14 | 1999-03-02 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞株 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009509544A (ja) * | 2005-10-01 | 2009-03-12 | チャールズ スタウト， | 調節可能な融合プロモーター |
| JP2016000047A (ja) * | 2005-10-01 | 2016-01-07 | スタウト， チャールズ | 調節可能な融合プロモーター |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2412637A1 (en) | 2002-01-03 |
| US6579522B1 (en) | 2003-06-17 |
| JP2012139220A (ja) | 2012-07-26 |
| EP1294918A2 (en) | 2003-03-26 |
| WO2002000906A3 (en) | 2002-06-06 |
| DE60114006D1 (de) | 2006-02-23 |
| EP1294918B1 (en) | 2005-10-12 |
| WO2002000906A2 (en) | 2002-01-03 |
| AU2001271549B2 (en) | 2005-06-09 |
| US20030175245A1 (en) | 2003-09-18 |
| ATE306555T1 (de) | 2005-10-15 |
| DE60114006T2 (de) | 2006-07-20 |
| AU7154901A (en) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012139220A (ja) | 複製欠損アデノウイルスｔｎｆベクター | |
| US20230054820A1 (en) | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin | |
| CA2836987C (en) | Chimeric adenoviruses for use in cancer treatment | |
| CA2173975C (en) | Recombinant adenoviral vector and methods of use | |
| US6210939B1 (en) | Recombinant adenoviral vector and methods of use | |
| US10046067B2 (en) | Decorin gene delivery system and cancer treatment | |
| AU2001271549A1 (en) | Replication deficient adenoviral TNF vector | |
| Wu et al. | Cancer gene therapy by adenovirus-mediated gene transfer | |
| JPH10505484A (ja) | 相補的なアデノウイルスベクター系と細胞系 | |
| BG62739B1 (bg) | Комплементарни аденовирусни векторни системи и клетъчни линии | |
| JP2001510998A (ja) | 変更されたヘキソン蛋白質を有するアデノウィルス | |
| US20070253932A1 (en) | Recombinant adenoviral vectors and methods of use | |
| AU699867B2 (en) | Recombinant adenoviruses for gene therapy in cancers | |
| KR20080090486A (ko) | 신규한 아데노바이러스를 이용한 암 치료 방법 및 조성물 | |
| JP2004519201A (ja) | キメラアデノウイルスベクター | |
| JP5550803B2 (ja) | 新規アデノウイルスを用いた癌治療方法及び組成物 | |
| US20030091534A1 (en) | Adenoviral vectors having a protein IX deletion | |
| JP2002527455A (ja) | 組換え欠失アデノウイルスベクター | |
| US20020137212A1 (en) | Adenoviral vectors having a protein IX deletion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080612 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110519 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110526 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110615 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110622 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110722 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110822 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120203 |